<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2007-11-18" updated="2020-01-02">
  <drugbank-id primary="true">DB05322</drugbank-id>
  <name>INGN 201</name>
  <description>INGN 201(Advexin) is a replication-impaired adenoviral vector that carries the p53 gene, has been evaluated in both preclinical and clinical trials. Advexin is a well-tolerated and efficacious treatment for numerous cancers, both as monotherapy and in combination with radiation and/or chemotherapy agents.</description>
  <cas-number/>
  <unii/>
  <state>solid</state>
  <groups>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A3375</ref-id>
        <pubmed-id>17472413</pubmed-id>
        <citation>Authors unspecified: INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201. Drugs R D. 2007;8(3):176-87.</citation>
      </article>
      <article>
        <ref-id>A3376</ref-id>
        <pubmed-id>16856803</pubmed-id>
        <citation>Gabrilovich DI: INGN 201 (Advexin): adenoviral p53 gene therapy for cancer. Expert Opin Biol Ther. 2006 Aug;6(8):823-32.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Investigated for use/treatment in bladder cancer, brain cancer, breast cancer, esophageal cancer, head and neck cancer, lung cancer, oral cavity cancer, ovarian cancer, and prostate cancer.</indication>
  <pharmacodynamics/>
  <mechanism-of-action>Advexin® is a vaccine that contains very high concentrations of the p53 protein. Advexin® is administered into or near the site of cancer and has demonstrated the ability to make cancer cells more sensitive to the killing effects of chemotherapy. The p53 gene makes protein that is responsible for stopping uncontrolled growth of a cell. One of its roles is to stop growth of a cell and initiate repair of any detected mutations or damage within the DNA of the cell. In addition, the p53 gene will direct the cell to destroy itself if a mutation or damage is detected that is beyond repair.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms/>
  <products/>
  <international-brands>
    <international-brand>
      <name>Advexin</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Biological Products</category>
      <mesh-id>D001688</mesh-id>
    </category>
    <category>
      <category>Complex Mixtures</category>
      <mesh-id>D045424</mesh-id>
    </category>
    <category>
      <category>Gene Transfer Techniques</category>
      <mesh-id>D018014</mesh-id>
    </category>
    <category>
      <category>Genes, p53</category>
      <mesh-id>D016158</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages/>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <sequences/>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347910081</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>